2002
DOI: 10.1212/wnl.58.10.1556
|View full text |Cite
|
Sign up to set email alerts
|

Long-term response to zonisamide in patients with West syndrome

Abstract: The long-term effectiveness of zonisamide (ZNS) was evaluated in 11 patients with West syndrome (7 symptomatic) who had cessation of spasms with ZNS monotherapy. During the follow-up period (24 to 79 months, mean = 53 months), this response was maintained in 7 patients (3 symptomatic, relapse rate = 36%), including 2 children in whom ZNS was successfully discontinued. No serious adverse reactions were noted. ZNS may be both effective and well tolerated for the treatment of West syndrome.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
13
0
3

Year Published

2004
2004
2020
2020

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 31 publications
(16 citation statements)
references
References 7 publications
0
13
0
3
Order By: Relevance
“…White cell number must be monitored. Good and excellent results are obtained either on spasms and/or hypsarrhythmia [113-115]. …”
Section: Treatmentmentioning
confidence: 99%
“…White cell number must be monitored. Good and excellent results are obtained either on spasms and/or hypsarrhythmia [113-115]. …”
Section: Treatmentmentioning
confidence: 99%
“…In another study, the long-term effectiveness of zonisamide was evaluated in 11 patients with West syndrome (7 symptomatic) who had cessation of spasms with zonisamide monotherapy. During the follow-up period (24 to 79 months), this response was maintained in 7 patients (relapse rate = 36%) 74. Recently, 6 of 23 (26%) patients with symptomatic infantile spasms became spasm-free on zonisamide 75…”
Section: Zonisamidementioning
confidence: 96%
“…Suzuki et al (2002) оценивали эффективность длительной терапии у 11 пациентов с синдромом Ве-ста (из них 7 -симптоматических случаев), у которых было отмечено прекращение эпилептических спазмов на монотерапии зонисамидом. За период катамнести-ческого наблюдения (от 24 до 79 мес, в среднем -53 мес) данный терапевтический ответ сохранялся у 7 пациентов (3 -симптоматические случаи синдро-ма Веста, частота рецидивов -36 %), включая 2 детей, у которых зонисамид был в дальнейшем отменен.…”
Section: эффективность зонисамида в лечении эпилепсииunclassified
“…Результаты исследования показали, что зониса-мид может быть эффективен в лечении синдрома Веста и хорошо переносится у этой категории паци-ентов [87].…”
Section: эффективность зонисамида в лечении эпилепсииunclassified